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Abstract
Introduction:  Preventing  or  reversing  hearing  loss  is  challenging  in  Ménière’s  disease.  Betahis-
tine, as  a  histamine  agonist,  has  been  tried  in  controlling  vertigo  in  patients  with  Ménière’s
disease, but  its  effectiveness  on  hearing  problems  is  not  known.
Objective:  To  examine  the  effect  of  betahistine  on  hearing  function  in  not-previously-treated
patients  with  Ménière’s  disease  and  to  deﬁne  possible  contributors  in  this  regard.
Methods: A  total  of  200  not-previously-treated  patients  with  deﬁnite  unilateral  Ménière’s  dis-
ease received  betahistine  by  mouth  (initial  dose,  16  mg  three  times  a  day;  maintenance  dose,
24--48 mg  daily  in  divided  doses).  Changes  in  indicators  of  hearing  status  before  and  six  months
after treatment  were  documented.  Hearing  loss  was  considered  as  the  mean  hearing  level
>25 dB  HL  at  ﬁve  frequencies.
Results:  The  mean  duration  of  disease  was  3.37  years.  Six  months  after  treatment  the  mean
hearing level  decreased  by  6.35  dB  compared  to  that  at  the  baseline  (p  <  0.001).  Both  patients’
age and  the  duration  of  disease  correlated  negatively  with  the  improvement  in  hearing  function.
Post treatment  hearing  loss  was  independently  associated  with  age,  the  initial  hearing  level  and
the chronicity  of  disease.  The  corresponding  optimal  cut-off  points  for  predicating  a  persistent
hearing loss  6  months  after  treatment  were  47  years,  38  dB  HL,  and  1.4  years,  respectively.
Conclusion:  Oral  betahistine  was  signiﬁcantly  effective  in  preventing/reversing  hearing  deteri-
oration in  patients  with  Ménière’s  disease.  Age,  the  hearing  level  on  admission,  and  the  disease
duration were  independent  predictors  of  hearing  status  after  treatment.
© 2015  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published
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PALAVRAS-CHAVE
Tratamento  médico;
Doenc¸a de  Ménière;
Perda  de  audic¸ão;
Prognóstico
Func¸ão auditiva  após  terapia  com  beta-histina  em  pacientes  com  doenc¸a de  Ménière
Resumo
Introduc¸ão:  Prevenir  ou  reverter  a  perda  auditiva  é  um  desaﬁo  na  doenc¸a  de  Ménière.  A  beta-
histina, um  agonista  de  histamina,  tem  sido  testada  no  controle  de  vertigem  em  pacientes  com
doenc¸a de  Ménière,  mas  sua  eﬁcácia  em  problemas  de  audic¸ão  ainda  não  é  conhecida.
Objetivo:  Analisar  o  efeito  da  beta-histina  na  func¸ão  auditiva  em  pacientes  com  doenc¸a  de
Ménière não  tratados  previamente,  e  deﬁnir  possíveis  contribuintes  a  esse  respeito.
Método:  Um  total  de  200  pacientes  sem  tratamento  prévio,  e  com  diagnóstico  deﬁnido  de
doenc¸a de  Ménière  unilateral,  recebeu  beta-histina  por  via  oral  (dose  inicial  de  16  mg  três
vezes ao  dia;  dose  de  manutenc¸ão  de  24--48  mg  por  dia,  em  doses  divididas).  Alterac¸ões  do
limiar auditivo  antes  e  após  seis  meses  de  tratamento  foram  documentadas.  Considerou-se
como perda  auditiva  uma  média  do  nível  de  audic¸ão  >25  dB  NA  em  cinco  frequências.
Resultados:  A  média  de  durac¸ão  da  doenc¸a  foi  de  3,37  anos.  Seis  meses  após  o  tratamento,  a
média do  limiar  auditivo  diminuiu  em  6,35  dB,  em  comparac¸ão  com  o  valor  da  linha  de  base
(p <  0,001).  Tanto  a  idade  dos  pacientes  quanto  a  durac¸ão  da  doenc¸a  apresentaram  correlac¸ão
negativa com  a  melhora  da  func¸ão  auditiva.  A  perda  auditiva  após  o  tratamento  foi  indepen-
dentemente  associada  à  idade,  ao  nível  inicial  de  audic¸ão  e  à  cronicidade  da  doenc¸a.  Os  pontos
de corte  ótimos  correspondentes  para  prever  uma  perda  auditiva  persistente  seis  meses  após  o
tratamento  foram  47  anos,  38  dB  HL  e  1,4  ano,  respectivamente.
Conclusão:  A  beta-histina  oral  foi  signiﬁcantemente  eﬁcaz  na  prevenc¸ão/reversão  da
deteriorac¸ão auditiva  em  pacientes  com  doenc¸a  de  Ménière.  Idade,  nível  de  audic¸ão  na  admis-
são e  durac¸ão  da  doenc¸a  foram  fatores  preditivos  independentes  da  condic¸ão  auditiva  após  o
tratamento.
© 2015  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado
por Elsevier  Editora  Ltda.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY  (http://
creativecommons.org/licenses/by/4.0/).
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aIntroduction
Described  for  the  ﬁrst  time  in  1861  by  Prosper  Ménière,
Ménière’s  disease  or  idiopathic  endolymphatic  hydrops  is
a  disorder  of  the  inner  ear.  Elevated  pressure  in  the
endolymph  can  cause  four  symptoms:  (1)  ﬂuctuating  sen-
sorineural  hearing  loss,  (2)  occasional  episodic  vertigo,  (3)
tinnitus,  and  (4)  aural  fullness.1
The  audiometric  pattern  of  hearing  loss  in  Ménière’s  dis-
ease  ﬂuctuates  by  time.  While  the  hearing  loss  is  limited  to
low  frequencies  in  the  early  stages,  medium  and  high  fre-
quencies  are  also  involved  during  the  progression  of  disease.
Appropriate  treatments,  however,  may  prevent,  or  at  least
defer  hearing  loss  in  Ménière’s  disease,  particularly  when
they  are  started  early  after  the  onset  of  symptoms.2
Since  the  disease  is  a  chronic  condition  that  evolves
over  a  rather  long  period  of  time,  time  series  analyses  are
required  for  evaluating  the  effectiveness  of  treatment  and
the  estimation  of  prognosis.3
Betahistine  (Serc)  is  a  histamine  agonist  that  has  been
found  effective  in  symptomatic  treatment  of  Ménière’s
disease.  Although  the  exact  mechanism(s)  of  action  is
unknown,  betahistine  is  thought  to  act  by  increasing  blood
ﬂow  to  the  cochlear  stria  vascularis  and/or  preventing  the
activity  of  the  vestibular  nuclei.4,5By  now,  some  studies  have  tried  to  test  the  actual  use-
fulness  of  this  medication  in  Ménière’s  disease,  but  because
the  majority  of  them  are  methodologically  ﬂawed,  reach-
ing  a  deﬁnite  conclusion  has  been  impossible.  This  is  why
t
e
setahistine  has  not  been  approved  by  the  US  Food  and  Drug
dministration  (FDA)  to  be  used  in  patients  with  Ménière’s
isease.6
In  spite  of  this,  Smith  et  al.7 reported  that  94%  of  oto-
aryngologists  in  the  United  Kingdom  prescribe  betahistine
o  their  Ménière’s  patients.  Similar  reports  are  available
rom  South  American  countries.8 To  the  best  of  the  authors’
nowledge,  however,  the  effectiveness  of  betahistine  in
reventing  or  ameliorating  hearing  loss  in  patients  with
énière’s  disease  has  not  been  tested.  Thus,  this  study
eeks  to  examine  the  effect  of  betahistine  therapy  on  hear-
ng  function  in  patients  with  no  previous  treatment  for
énière’s  disease,  and  to  deﬁne  possible  related  contrib-
tors.
ethods
atients
 total  of  200  not-previously-treated  patients  with  deﬁ-
ite  Ménière’s  disease  were  consecutively  recruited  from  a
eaching  clinic  between  2011  and  2013.  The  ethics  commit-
ee  of  a  local  university  approved  this  study  (no.  5/4/6629),
nd  written  informed  consents  were  obtained  from  the  par-
icipants.
Subjects  with  probable/possible  Ménière’s  disease,  bilat-
ral  involvement,  prior  otological  surgery,  or  underlying
ystemic  diseases  were  not  included.
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Table  1  Demographic  data  and  baseline  variables  in  200
patients  with  Ménière’s  disease.
Sex
Male  67  (33.5)
Female  133  (66.5)
Age (year)  45.29  ±  12.16  (18--78)
Disease  duration  (month)  40.44  [1.20]  (1--260.4)
Symptoms
Vertigo 200  (100)
Tinnitus/aural  fullness 200  (100)
Hearing  problems 186  (93)
Disease  stage
I  72  (36)
II 71  (35.5)
III 54  (27)
IV 3  (1.5)
Hearing  level  (dB  HL) 33.32  [1.27]  (10--100)
Hearing  loss  129  (64.5)
R
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ing  improvement  in  60  patients  (30%)  at  the  endpoint.
Six  months  after  treatment  a  retained  hearing  loss  was
detected  in  90  patients,  indicating  a  30.23%  decrease  by  the
treatment  (McNemar  test  p  <  0.001).
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The  diagnosis  and  grading  of  Ménière’s  disease  was
ccording  to  the  guidelines  offered  by  the  American
cademy  of  Otolaryngology  --  Head  and  Neck  Surgery.9
Each  patient  underwent  otoscopy  and  audiometry  under
uiescent  state  without  vertiginous  attack  at  baseline  and
ix  months  post  treatment.
udiometry
 standard  audiometer  (Amplivox  270,  Amplivox,  Oxford-
hire,  England)  was  used  for  the  measurement  of  hearing
hresholds.  At  four  frequencies  (500,  1000,  2000,  and
000  Hz)  the  four  tone  average  was  calculated  from  the
orst  audiogram  during  the  interval  of  three  months  before
nd  six  months  after  treatment.9 The  average  hearing  level
t  ﬁve  frequencies  (250,  500,  1000,  2000,  and  4000  Hz)  was
sed  in  deﬁning  hearing  loss  (the  mean  hearing  level  >25  dB
L).10
reatment
atients  received  betahistine  dihydrochloride  (Betaserc,
 mg  tablet,  Abbott,  Illinois,  USA)  by  mouth,  initially  16  mg
hree  times  a  day,  with  food,  at  a  maintenance  dose  of
4--48  mg  daily  divided  in  doses  to  control  symptoms.11,12
General  dietary  recommendations  such  as  low  sodium
ntake  were  implemented,  but  no  other  medication  except
or  betahistine  was  allowed  during  the  study  period.
utcome  measures
mprovement  in  the  hearing  level  six  months  after  treatment
IHL6):  hearing  level  at  baseline  --  hearing  level  6  months
fter  treatment.
Hearing  improvement:  IHL6 >  0
Hearing  loss:  six-month  post  treatment  mean  hearing  level
>25  dB  HL.10
tatistical  analysis
he  SPSS  software  version  19.0  (IBM  Corporation,
ew  York,  USA)  was  used  for  statistical  analysis.
istribution  of  numeric  data  was  tested  using  the
olmogorov--Smirnov  method.  The  numeric  data  were
hown  as  the  mean  ±  standard  deviation  or  the  mean
standard  error  of  the  mean,  SEM].  The  contingency
ables  (Pearson  chi-square  test),  McNemar  test,  indepen-
ent  samples  t test,  paired  samples  t  test,  independent
ann--Whitney  U  test,  and  Wilcoxon  signed  ranks  test
ere  used,  when  appropriate.  The  Spearman’s  coefﬁcient
rho)/Pearson  coefﬁcient  (r)  was  calculated  to  investigate
orrelations  between  variables.  A  stepwise  descending
ogistic  regression  analysis/linear  regression  model  was
sed  in  constructing  a  multivariate  analysis.  The  receiver
perator  characteristics  (ROC)  curve  was  drawn  in  deter-
ining  areas  under  the  curve  and  optimal  cut-off  values.  A
igniﬁcance  level  was  set  at  p  ≤  0.05.
F
s
iData are presented as frequency (%), mean ± standard deviation
(range), or mean [standard error of the mean] (range).
esults
he  study  variables  including  demographic  information  and
eneral  data  at  the  time  of  admission  are  summarized  in
able  1.
Six  months  post  treatment  the  mean  hearing  level
ropped  signiﬁcantly  at  26.97  dB  HL  (SEM,  1.42;  percent
ecrease,  19.06%;  Wilcoxon  signed  ranks  test  p  <  0.001)
Fig.  1).
The  mean  IHL6 was  6.35  dB  (SEM,  0.75),  denoting  a  hear-igure  1  Changes  in  the  mean  hearing  levels  at  baseline  and
ix months  after  treatment.  Error  bars  represent  95%  conﬁdence
nterval.  *p  ≤  0.05  is  statistically  signiﬁcant.
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speciﬁcity:  56.1%)  and  1.4  (sensitivity:  63.5%,  speciﬁcity:
68%),  respectively  (Fig.  3).
Persistent  hearing  loss
Variables  in  relation  to  persistent  hearing  loss  after  treat-
ment  are  summarized  in  Table  2. Accordingly,  advanced
age  (independent  samples  t  test  p  =  0.01),  male  gen-
der  (chi-square  test  p  =  0.05),  a  more  chronic  disease
(Mann--Whitney  U  test  p  <  0.001)  and  a  high  baseline  hear-
ing  level  (Mann--Whitney  U  test  p  <  0.001)  were  signiﬁcantly
associated  with  persistent  hearing  loss  after  treatment.
Age
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Figure  3  Receiver  operator  characteristics’  curves  ofFigure  2  Simple  scatterplots  representing  reverse  correlatio
months after  treatment  (IHL6)  (A)  and  between  disease  duratio
Contributors to hearing function after
treatment
IHL6
The  mean  IHL6 was  6.99  dB  (SEM,  0.08)  in  females  and
5.07  dB  (SEM,  0.14)  in  males  (Mann--Whitney  U  test  p  =  0.23).
A  signiﬁcant,  reverse  correlation  was  seen  between  age  and
IHL6 (Pearson  r  =  −0.16,  p  =  0.03)  (Fig.  2  A),  indicating  a  neg-
ative  connection  between  increasing  age  and  improvement
in  hearing  function  after  treatment.  There  was  no  signiﬁ-
cant  correlation  between  IHL6 and  the  baseline  hearing  level
(Spearman’s  rho  =  0.09,  p  =  0.21),  whereas  a  negative,  signif-
icant  correlation  was  present  between  IHL6 and  the  duration
of  disease  (Spearman’s  rho  =  −0.31,  p  <  0.001)  (Fig.  2B).
In  a  linear  regression  model,  both  age  and  the  duration
of  disease  were  independently  associated  with  IHL6 (p  =  0.05
and  0.002,  respectively).
Hearing  improvement
Males  and  females  had  similar  hearing  improvement  rates
after  treatment  (25.4%  vs.  32.3%,  respectively;  chi-square
test  p  =  0.31).  Patients  with  hearing  improvement,  how-
ever,  were  signiﬁcantly  younger  (41.60  ±  11.46  years  vs.
46.86  ±  12.14  years;  independent  samples  t  test  p  =  0.01).
The  mean  disease  duration  was  signiﬁcantly  lower  in  the
cases  with  hearing  improvement  than  in  those  with  no
change  or  deterioration  in  hearing  function  six  months
after  treatment  (1.71[0.28]  years  vs.  3.26[0.39]  years;
Mann--Whitney  U  test  p  <  0.001).  The  mean  baseline  hearing
level  was  33.75  dB  HL  (SEM,  1.31)  in  patients  with  hearing
improvement  and  33.14  dB  HL  (SEM,  1.72)  in  the  remaining
ones  (Mann--Whitney  U  test  p  =  0.79).
In  multivariate  analysis  both  age  and  disease  dura-
tion  were  independent  determinants  of  post  treatment
hearing  improvement  (p  =  0.01,  Exp(B) =  0.96  and  p  =  0.002,
Exp(B)  =  1.00,  respectively).  With  areas  under  the  ROC
curves  of  0.62  (p  =  0.01)  and  0.69  (p  <  0.001),  the
related  optimal  cut-off  points  were  44  (sensitivity:  57.3%,
patients’  age  and  disease  duration  in  predicting  unfavorable
hearing  function  six  months  after  treatment.  Area  under  the
curve:  0.62  for  age  and  0.69  for  disease  duration  (p  =  0.01  and
<0.001,  respectively).
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Table  2  Study  variables  in  patients  with  persistent  and  resolved  hearing  loss  (HL)  six  months  after  treatment.
Variables  Persistent  HL  (n  =  90)  Resolved  HL  (n  =  39)  p-Value
Sex  (female)  53  (58.9)  30  (76.9)  0.05a
Age  (year)  49.73  ±  12.74  43.15  ±  11.19  0.01a
Disease  duration  (year)  4.28  [0.05]  1.71  [0.06]  <0.001a
Hearing  level  (dB  HL)  47.20  [1.45]  35.64  [1.07]  <0.001a
Data are shown as frequency (%), mean ± standard deviation, or mean [standard error of the mean].
Hearing loss (HL), indicates mean hearing level of ﬁve frequencies >25 dBn HL.
a p-Value ≤ 0.05 is statistically signiﬁcant.
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Figure  4  Receiver  operator  characteristics’  curves  of
patients’  age,  baseline  hearing  level,  and  disease  duration  in
predicting  persistent  hearing  loss  six  months  after  treatment.
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wrea under  the  curve:  0.66  for  age,  0.76  for  baseline  hear-
ng level,  and  0.75  for  disease  duration  (p  =  0.01,  <0.001,  and
0.001,  respectively).
In  multivariate  analysis,  except  for  sex  (p  =  0.11,
xp(B)  = 2.41),  all  the  remaining  variables  including  age
p  = 0.01,  Exp(B) =  1.06),  disease  chronicity  (p  =  0.01,
xp(B)  = 1.00)  and  baseline  hearing  level  (p  <  0.001,
xp(B)  = 1.10)  were  found  as  independent  contributors  to
he  post  treatment  hearing  function.
The  related  ROC  curves  of  age,  disease  chronicity  and
aseline  hearing  level  are  shown  in  Fig.  4.  With  areas  under
he  ROC  curves  of  0.66  (p  =  0.01),  0.75  (p  <  0.001)  and  0.76
p  < 0.001),  the  optimal  cut-off  points  were  47  (sensitivity:
0.7%,  speciﬁcity:  58.3%),  1.4  (sensitivity:  67.4%,  speci-
city:  69.4%)  and  38  (sensitivity:  76.4%,  speciﬁcity:  63.9%),
espectively.
iscussionlthough  a  large  variability  exists  as  to  the  symptoms
ppearing  in  the  course  of  Ménière’s  disease,  hearing
oss  is  usually  accounted  as  an  inevitable  consequence.13
n  contrast  to  the  outdated  notion  of  ‘‘natural  history’’
n
g
bhat  suggests  neither  surgical  nor  pharmacologic  inter-
entions  could  alter  hearing  deterioration  in  Ménière’s
isease,14--16 timely  diagnosis  and  early  treatment  could
emarkably  impede  its  progression.17 An  average  improve-
ent  of  6.35  dB  in  hearing  level  six  months  after  the
dministration  of  betahistine  in  the  present  study  supports
his  fact.
A  younger  age  and  shorter  duration  of  the  disease
ere  two  independent  predictors  of  post  treatment  hearing
mprovement  in  this  work.  Similarly,  in  a  study  on  pure  tone
udiograms  of  300  patients  with  Ménière’s  disease,  Papar-
lla  et  al.18 found  the  duration  of  disease  as  an  important
rognostic  factor  in  relation  to  alterations  in  hearing  func-
ion.  In  another  retrospective  series,  Katsarkas19 examined
75  patients  suffering  from  Ménière’s  disease  and  found  that
espite  case-to-case  variations  in  hearing  loss,  the  hear-
ng  impairment  correlated  signiﬁcantly  over  time  with  the
lapsed  time  since  the  onset  of  the  disease.  In  a  retrospec-
ive  study  on  243  patients  with  Ménière’s  disease  by  Havia
t  al.,20 prolonged  disease  was  associated  with  deterioration
f  hearing  function.  In  a  very  recent  study  by  Sato  et  al.,21
otential  factors  in  connection  with  the  prognosis  of  hearing
oss  were  examined  retrospectively  in  a  group  of  36  patients
ith  unilateral  Ménière’s  disease.  They  reported  that  the
ean  interval  from  the  onset  of  the  disease  to  the  initial
isit  was  signiﬁcantly  longer  in  patients  with  poor  hearing.
ikewise,  a similar  connection  has  been  suggested  between
ge  and  hearing  impairment  in  patients  with  Ménière’s
isease.22,23 To  the  best  of  the  authors’  knowledge,  how-
ver,  this  is  the  ﬁrst  study  that  reports  an  independent  role
f  age  in  determining  hearing  function  and  its  responsiveness
o  medical  treatment  with  betahistine  in  Ménière’s  disease.
Considering  the  effect  of  treatment  on  hearing  loss  (i.e.
he  mean  hearing  level  of  ﬁve  frequencies  >25  dB  HL),  the
ercentage  of  patients  affected  by  this  problem  decreased
igniﬁcantly  from  64.5%  at  the  baseline  to  45%  at  the  end-
oint  (p  <  0.001).  In  addition  to  age  and  the  duration  of
isease,  admitting  hearing  level  (in  multivariate  study)  and
ex  (in  univariate  study)  were  other  predicting  factors  in  this
egard.
In  terms  of  hearing  prognosis,  a  compromised  hearing
bility  at  the  initial  visit  may  augur  ill  for  the  future  in
atients  with  Ménière’s  disease.21 Sato  et  al.21 also  found
hat  the  hearing  levels  at  the  initial  visits  were  signiﬁcantly
orse  in  patients  with  poor  than  in  those  with  good  prog-
oses.
Cochlear  and  eighth  cranial  nerve  injuries  have  been  sug-
ested  as  plausible  underlying  causes  of  Ménière’s  disease
y  some  investigators.  Relative  preservation  of  hair  cells
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at  the  same  points  of  injury  further  corroborates  the  the-
ory  of  neurotoxicity  in  such  patients.  It  has  been  found
that  nerve  deterioration  is  possibly  independent  of  hydrops
severity.24 This  may  explain  the  heterogeneity  found  in  this
study  in  terms  of  the  prognostic  role  of  initial  hearing  level,
which  was  signiﬁcantly  associated  with  persistent  hearing
loss  but  not  with  the  degree  of  improvement  in  hearing  func-
tion  after  treatment.  That  is  to  say,  structural  rather  than
functional  abnormalities  go  along  with  permanent  hearing
loss  that  does  not  respond  adequately  to  medical  treat-
ments.  Presence  of  hearing  loss  may  indicate  such  structural
changes  in  patients  with  Ménière’s  disease.18
In  a  similar  study  that  attempted  to  identify  factors  in
association  with  the  responsiveness  to  medical  management
of  Ménière’s  disease,  Devaiah  and  Ato25 studied  29  patients.
They  found  that  aggressive  medical  therapy  (sodium  restric-
tion  and  diuretic  treatment  in  this  series)  may  prevent
disease  progression  in  terms  of  hearing  loss  in  those  with
less  severe  disease.
In  the  current  work  the  authors  tried  to  deﬁne  cut-off
points  for  age,  the  initial  hearing  loss,  and  the  duration  of
disease.  Using  ROC  curve  analysis,  the  corresponding  values
were  47  (sensitivity:  60.7%,  speciﬁcity:  58.3%),  38  (sensitiv-
ity:  76.4%,  speciﬁcity:  63.9%),  and  1.4  (sensitivity:  67.4%,
speciﬁcity:  69.4%),  respectively.
In  a  study  by  Kotimaki  et  al.23 the  records  of  205  patients
with  deﬁnite  diagnosis  of  Ménière’s  disease  were  retrospec-
tively  reviewed.  They  showed,  in  line  with  our  ﬁndings,  that
both  age  and  the  duration  of  disease  are  associated  with
hearing  impairment,  with  deterioration  in  pure-tone  aver-
age  over  the  frequencies  0.5--4  kHz  by  approximately  1  dB
per  year  due  to  the  duration  of  disease  and  by  approximately
0.5  dB  per  year  because  of  aging.  In  this  study  the  age  of
50  years  was  reported  as  a  determinant  of  the  role  of  the
duration  of  disease  in  affecting  hearing  loss.  Although  the
age  of  47  years  in  the  present  study  was  associated  with
persistent  hearing  loss  after  treatment  independent  of  the
duration  of  disease,  their  reported  ﬁgure  approximates  ours.
In  normal  people  the  rate  of  hearing  loss  by  aging  at  vari-
ous  frequencies  may  differ  between  males  and  females.  This
gender-related  difference  may  explain  our  ﬁnding  in  terms
of  the  effect  of  sex  on  the  responsiveness  of  hearing  loss  to
medical  treatment.  More  studies,  however,  are  needed  to
draw  a  solid  conclusion  in  this  regard.23
In  the  present  work  we  excluded  patients  with  bilateral
disease  because  bilaterality  has  been  suggested  as  a  pre-
dicting  factor  for  poor  hearing  prognosis  in  patients  with
Ménière’s  disease1,18 and  it  could  have  interfered  with  the
main  objective  of  this  study.
Another  limitation  of  the  present  work  was  a  relatively
short  follow-up  of  hearing  condition  after  treatment  (six
months).  Longer  follow-ups  may  be  required  in  this  regard.26
Patients  recruited  in  this  study  were  diagnosed  recently
as  cases  with  Ménière’s  disease.  Medical  records  and
patients’  declarations  were  the  only  documents  we  relied
on  to  evaluate  history  and  possible  previous  treatments.  This
may  decrease  the  reliability  of  employed  data  in  this  work.
Despite  statistically  signiﬁcant  hearing  improvements
detected  in  the  current  study,  these  changes  might  not  be
clinically  advantageous.  It  should  be  acknowledged  that  it
was  not  possible  to  verify  if  the  patients  were  in  an  inter-
crises  period,  when  the  hearing  is  usually  better.  That  could
1
1505
ave  happened  for  the  patients  presenting  with  mild  losses,
nd  so,  reaching  uniform  clinical  outcomes  could  have  been
ffected  adversely.
The  ﬁnal  limitation  was  that  only  the  results  of  a
onservative,  not  consensually  accepted  medical  treat-
ent  (i.e.  betahistine)  were  considered  in  this  study.  This
pproach  was  chosen  because  nonpharmacologic  treatments
re  diverse  and  their  outcome  varies  signiﬁcantly  between
tudies.14--16 In  addition,  as  mentioned  before,  in  many
ountries  such  as  in  the  United  Kingdom  and  many  South
merican  countries  this  medication  is  widely  used  for  symp-
omatic  treatment  of  Ménière’s  disease.7,8
onclusion
ased  on  the  ﬁndings  of  this  study,  oral  betahistine  is  effec-
ive  in  preventing/correcting  hearing  problems  in  patients
ith  Ménière’s  disease.  Age  and  the  duration  of  disease
ndependently  contributed  to  the  effectiveness  of  the  med-
cation.  Sex  and  the  initial  hearing  level  may  also  play  a  role
n  this  regard.
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